The Contribution of Viral Proteins to the Synergy of Influenza and Bacterial Co-Infection

Viruses. 2022 May 16;14(5):1064. doi: 10.3390/v14051064.

Abstract

A severe course of acute respiratory disease caused by influenza A virus (IAV) infection is often linked with subsequent bacterial superinfection, which is difficult to cure. Thus, synergistic influenza-bacterial co-infection represents a serious medical problem. The pathogenic changes in the infected host are accelerated as a consequence of IAV infection, reflecting its impact on the host immune response. IAV infection triggers a complex process linked with the blocking of innate and adaptive immune mechanisms required for effective antiviral defense. Such disbalance of the immune system allows for easier initiation of bacterial superinfection. Therefore, many new studies have emerged that aim to explain why viral-bacterial co-infection can lead to severe respiratory disease with possible fatal outcomes. In this review, we discuss the key role of several IAV proteins-namely, PB1-F2, hemagglutinin (HA), neuraminidase (NA), and NS1-known to play a role in modulating the immune defense of the host, which consequently escalates the development of secondary bacterial infection, most often caused by Streptococcus pneumoniae. Understanding the mechanisms leading to pathological disorders caused by bacterial superinfection after the previous viral infection is important for the development of more effective means of prevention; for example, by vaccination or through therapy using antiviral drugs targeted at critical viral proteins.

Keywords: Streptococcus pneumoniae; co-infection; influenza viral proteins; influenza virus; secondary bacterial infection.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents
  • Bacterial Infections* / complications
  • Coinfection*
  • Humans
  • Influenza A virus* / physiology
  • Influenza, Human* / complications
  • Superinfection*
  • Viral Proteins

Substances

  • Antiviral Agents
  • Viral Proteins

Grants and funding

This work was supported by research grants APVV-17–0445 (EV) from The Slovak Research and Development Agency of the Slovak Republic and grants VEGA No. 2/0048/19 (EV) and VEGA No. 2/0090/21 (KT) from The Scientific Grant Agency of the Ministry of Education, Science, Research and Sport of Slovak Republic and Slovak Academy of Sciences.